Key Highlights
- On June 24, 2026, Eli Lilly finalized its purchase of Centessa Pharmaceuticals, delivering $38 cash per share to investors.
- Investors received additional non-transferable contingent value rights worth as much as $9 per share.
- Following the deal’s closure, Centessa was removed from Nasdaq trading and operates as a fully owned Lilly entity.
- A comprehensive management restructuring occurred, with all existing Centessa executives and directors stepping down.
- The transaction places Centessa’s total value near $7.8 billion, focusing on sleep disorder therapeutics.
On June 24, 2026, Eli Lilly successfully finalized its purchase of Centessa Pharmaceuticals, delivering a cash payment of $38 for each share — alongside contingent value rights potentially worth up to $9 per share — in a transaction totaling approximately $7.8 billion.
The deal closed via Lilly’s acquisition vehicle, LDH XV Corporation, after receiving authorization through a UK court-approved scheme of arrangement dated June 22, 2026.
Centessa Pharmaceuticals plc, CNTA
CNTA shares reached a record peak of $40.26 before the deal’s completion, representing a 183% price increase year-over-year and a 209% gain on a total return measurement.
At its peak, Centessa’s total market valuation reached $6.22 billion — demonstrating investor anticipation of the transaction’s finalization.
Effective June 24, Centessa transitioned into a completely owned Lilly division. Previous equity holders forfeited all ownership privileges, receiving solely the agreed-upon transaction payment.
The organization promptly initiated procedures to withdraw its American Depositary Shares from Nasdaq and cease its public disclosure requirements.
Centessa simultaneously settled and closed out its loan and security arrangement with Oxford Finance alongside other creditors as part of the closing procedures.
Complete Management Overhaul
The acquisition prompted an extensive organizational transformation. Every senior executive and board member at Centessa exited their positions when the deal became effective.
Lilly designated two replacement directors who assumed control of the reconfigured board. The company’s at-the-market equity distribution initiative was simultaneously discontinued.
Centessa’s metamorphosis is now final — evolving from a standalone, Nasdaq-traded biotechnology firm into a wholly incorporated division within Lilly’s organizational framework.
Wall Street Response
Financial analysts had previously adjusted their assessments to mirror the transaction parameters. Truist Securities revised CNTA from Buy to Hold after the deal announcement, establishing a $38 price objective — matching the cash payment amount.
Wolfe Research executed a comparable adjustment, transitioning its position from Outperform to Peerperform.
The latest analyst evaluation for CNTA stands at Hold with a $42 target price — marginally exceeding the acquisition price, factoring in the possible CVR distribution.
Lilly’s strategic motivation focuses on strengthening its development portfolio within the sleep disorder therapeutic area, a segment where Centessa had been advancing multiple initiatives.
The Alkermes correlation merits attention: upon the initial Centessa announcement, Alkermes shares climbed 13%, indicating wider market enthusiasm for sleep disorder therapeutics.
Following delisting completion and Centessa’s full integration, CNTA shares no longer exist as publicly available securities.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
